Sinovac begins payment of $55 per share special cash dividend

BEIJING - Sinovac Biotech Ltd. (NASDAQ:SVA), currently trading at $0.12 per share with a market capitalization of $37.16 million, has started distributing its previously declared special cash dividend of $55.00 per common share to shareholders who owned the company’s stock as of July 7, 2025, according to a company statement. According to InvestingPro analysis, the stock appears fairly valued based on its Fair Value assessment.

The biopharmaceutical company, which has seen its stock decline 31% year-to-date and currently carries a WEAK financial health score according to InvestingPro, confirmed that dividend checks for record holders are being sent via overnight delivery services on Wednesday, with payments of $100 million or more being processed through wire transfers. Shareholders whose investments are managed through brokers will receive payments after their brokers submit the required documentation to the paying agent.

"For brokers who have already provided the broker letter to the Paying Agent, the dividend payment will be wired to the broker starting July 9, 2025," the company stated in its press release.

The company noted that while most beneficial shareholders should see the dividend credited to their accounts on the same day the broker receives the wire transfer, some may experience a delay until the next business day if the transfer arrives late in the day.

Sinovac, which focuses on developing and manufacturing vaccines against infectious diseases including COVID-19, hepatitis A, and influenza, said its board will continue to prioritize dividend distributions according to its previously announced policy.

Shareholders with questions about the dividend payment process can contact the appointed dividend information agent, D.F. King & Co., Inc., the company added.

In other recent news, Sinovac Biotech has been at the center of significant developments concerning its board and dividend payments. The company announced it will accelerate its previously declared $55 per share special dividend to be paid on July 7, 2025. Additionally, Sinovac declared a second special cash dividend of $19 per share, with a potential extra $3.73 per share contingent on certain legal outcomes. These announcements come amid a governance dispute with a group of dissenting investors, including Advantech/Prime Success and Vivo Capital, who are challenging the legitimacy of the current board.

Sinovac’s board, installed by Privy Council order, is urging shareholders to reject proposals to remove them at an upcoming Special Meeting. They have emphasized their commitment to regular dividend distributions and are exploring potential listings on the Hong Kong Stock Exchange. Meanwhile, Vivo Capital, holding an 8% stake, has publicly contested Sinovac’s governance claims and expressed concerns over recent board actions, such as the resignation of the independent auditor and delayed SEC filings. This delay has led to a NASDAQ non-compliance notification, requiring Sinovac to submit a compliance plan by mid-July. The ongoing legal and governance disputes have kept Sinovac’s stock trading halted since 2019.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.